ClinicalTrials.gg
CompletedNCT01552850Updated Aug 31, 2015

Pharmacokinetics And Relative Bioavailability Study Of Oxycodone

A Phase 1 interventional study of Oxycodone and Oxycodone in Pain, sponsored by Pain Therapeutics. Completed at 1 site in Singapore. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-31.

Sponsored by Pain Therapeutics · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing oxycodone in Pain — 4 open to participants now, 5 under way, 1 of them phase 3. Oxycodone · Pain.

Enrollment
43rd of 50
18 · median 67
Started
2012
with 5 others
Phase 1
10 of 50
2 open now
Registered
15th of 50
by date
Lead sponsor
3 of 50
Pain Therapeutics

Among the 50 studies testing oxycodone in Pain, this one is the 43rd largest by enrollment, is one of 6 that started in 2012, is one of 10 in phase 1, and was the 15th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 50 studies testing oxycodone in Pain are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About oxycodone

Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 21 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing oxycodone in Pain, or all of them as a file.
02

Study summary

To estimate the pharmacokinetics and relative bioavailability of oxycodone after administration of 40 mg doses of four PF-00345439 formulations and oxycodone in solution

Read the detailed description

This study will estimate the PK and relative bioavailability of oxycodone following single oral 40-mg doses of 3 modified PF-00345439 Formulations B, C, and D compared with the reference Formulation A under fed conditions.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • pharmacokinetics
  • relative bioavailability
  • oxycodone
04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of diseases
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Oxycodone Formulation A Capsule

    single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block

    Drug: Oxycodone

  • Experimental
    Oxycodone Formulation B Capsule

    single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block

    Drug: Oxycodone

  • Experimental
    Oxycodone Formulation C Capsule

    single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block

    Drug: Oxycodone

  • Experimental
    Oxycodone Formulation D Capsule

    single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block

    Drug: Oxycodone

  • Experimental
    Oxycodone Oral Solution

    40 mg oxycodone oral solution (5 mg/5 ml) under 50 mg naltrexone block

    Drug: Oxycodone

Interventions

  • 1X40 mg PF-00345439 formulation A capsule with water and under fed condition

  • 1X40 mg PF-00345439 formulation B capsule with water and under fed condition

  • 1X40 mg PF-00345439 formulation C capsule with water and under fed condition

  • 1X40 mg PF-00345439 formulation D capsule with water and under fed condition

  • 40 mg oxycodone oral solution (5 mg/5 ml) with water and under fed condition

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) (if data permit, otherwise Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUClast]) of oxycodone.

    Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose

  2. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose

Secondary outcomes

  1. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of oxycodone, as data permit.

    Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax) of oxycodone, as data permit.

    Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose

  3. Plasma Decay Half-Life of oxycodone, as data permit.

    Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose

  4. Concentration at time 24 hours (C24) of oxycodone, as data permit.

    Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose

  5. Adverse events, vital signs and laboratory parameters.

    Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose

07

Study locations

1 site
  • Pfizer Investigational Site
    Singapore, 188770, Singapore
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2012
First posted
Mar 13, 2012
Start
Apr 2012
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Last update
Aug 31, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01552850
Lead sponsor
Pain Therapeutics
Responsible party
Sponsor
First posted
Mar 13, 2012
Start date
Apr 2012
Primary completion
Jun 2012
Completion
Jun 2012
Last update
Aug 31, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone

Start the discussion